322 related articles for article (PubMed ID: 32972877)
21. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
[TBL] [Abstract][Full Text] [Related]
22. Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
Sebastian NT; McElroy JP; Martin DD; Sundi D; Diaz DA
Urol Oncol; 2019 Nov; 37(11):813.e11-813.e19. PubMed ID: 31109836
[TBL] [Abstract][Full Text] [Related]
23. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
Jackson WC; Hartman HE; Dess RT; Birer SR; Soni PD; Hearn JWD; Reichert ZR; Kishan AU; Mahal BA; Zumsteg ZS; Efstathiou JA; Kaffenberger S; Morgan TM; Mehra R; Showalter TN; Krauss DA; Nguyen PL; Schipper MJ; Feng FY; Sandler HM; Hoskin PJ; Roach M; Spratt DE
J Clin Oncol; 2020 Sep; 38(26):3024-3031. PubMed ID: 32396488
[TBL] [Abstract][Full Text] [Related]
24. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
25. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
[TBL] [Abstract][Full Text] [Related]
26. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
[TBL] [Abstract][Full Text] [Related]
27. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
28. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.
Löser A; Beyer B; Carl CO; Löser B; Nagaraj Y; Frenzel T; Petersen C; Krüll A; Graefen M; Schwarz R
Strahlenther Onkol; 2019 May; 195(5):374-382. PubMed ID: 30390115
[TBL] [Abstract][Full Text] [Related]
29. Surgery associated with increased survival compared to radiation in clinically localized Gleason 9-10 prostate cancer: a SEER analysis.
Nemirovsky A; Huang H; Al Kibria GM; Naslund M; Siddiqui MM
World J Urol; 2021 Feb; 39(2):415-423. PubMed ID: 32350585
[TBL] [Abstract][Full Text] [Related]
30. Primary radiotherapy for nonsurgically managed Stage I endometrial cancer: Utilization and impact of brachytherapy.
Gill BS; Chapman BV; Hansen KJ; Sukumvanich P; Beriwal S
Brachytherapy; 2015; 14(3):373-9. PubMed ID: 25600451
[TBL] [Abstract][Full Text] [Related]
31. Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy.
Guo Y; Mao S; Zhang A; Zhang J; Wang L; Wang R; Zhang W; Zhang Z; Wu Y; Cao X; Yang B; Yao X
Front Oncol; 2019; 9():638. PubMed ID: 31380277
[No Abstract] [Full Text] [Related]
32. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients.
Miccio JA; Talcott WJ; Jairam V; Park HS; Yu JB; Leapman MS; Johnson SB; King MT; Nguyen PL; Kann BH
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):414-422. PubMed ID: 32989262
[TBL] [Abstract][Full Text] [Related]
33. Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer.
Goy BW; Burchette R; Soper MS; Chang T; Cosmatos HA
Urology; 2020 Feb; 136():180-189. PubMed ID: 31704459
[TBL] [Abstract][Full Text] [Related]
34. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer.
Slevin F; Zattoni F; Checcucci E; Cumberbatch MGK; Nacchia A; Cornford P; Briers E; De Meerleer G; De Santis M; Eberli D; Gandaglia G; Gillessen S; Grivas N; Liew M; Linares Espinós EE; Oldenburg J; Oprea-Lager DE; Ploussard G; Rouvière O; Schoots IG; Smith EJ; Stranne J; Tilki D; Smith CT; Van Den Bergh RCN; Van Oort IM; Wiegel T; Yuan CY; Van den Broeck T; Henry AM
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38151440
[TBL] [Abstract][Full Text] [Related]
35. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
36. Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis.
Acharya S; Perkins SM; DeWees T; Fischer-Valuck BW; Mutch DG; Powell MA; Schwarz JK; Grigsby PW
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):649-57. PubMed ID: 26461007
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.
Smolska-Ciszewska B; Miszczyk L; Białas B; Fijałkowski M; Plewicki G; Gawkowska-Suwińska M; Giglok M; Behrendt K; Nowicka E; Zajusz A; Suwiński R
Radiat Oncol; 2015 Mar; 10():60. PubMed ID: 25884489
[TBL] [Abstract][Full Text] [Related]
39. Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis.
Aydh A; Motlagh RS; Abufaraj M; Mori K; Katayama S; Grossmann N; Rajwa P; Mostafai H; Laukhtina E; Pradere B; Quhal F; Schuettfort VM; Briganti A; Karakiewicz PI; Fajkovic H; Shariat SF
Arab J Urol; 2022; 20(2):71-80. PubMed ID: 35530569
[TBL] [Abstract][Full Text] [Related]
40. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients.
Miszczyk M; Magrowski Ł; Krzysztofiak T; Stando R; Majewski W; Stawiski K; Masri O; Ciepał J; Depowska G; Chimiak K; Bylica G; Czapla B; Masri M; Cichur F; Jabłońska I; Gmerek M; Nowicka Z; Wojcieszek P; Sadowski J; Suwiński R; Rajwa P; Goldner G; Moll M
Radiother Oncol; 2023 Jun; 183():109632. PubMed ID: 36963442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
